Vivacitas Oncology to Present a Poster on AR-67 at the 3rd Annual Glioblastoma Drug Development Summit
18. Januar 2022 09:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc., a privately-held oncology company focused on tough-to-treat cancers, will be attending and presenting a poster on...
Dr. Erkut Borazanci, MD, Joins Vivacitas Oncology's Pancreatic Medical Advisory Board
17. Januar 2022 09:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc., a privately-held oncology company focused on tough-to-treat cancers, proudly announces that Dr. Erkut Borazanci, MD,...
Vivacitas Oncology, Inc. to Present on AR-67 at the Annual 5th Meridian Clinical Trials Conference
22. November 2021 12:30 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc., a privately-held oncology company focused on tough-to-treat cancers, will present its lead development candidate,...
National Brain Tumor Society Supported Work Features in 19 Presentations at 2018 Society for Neuro-Oncology Annual Meeting
13. November 2018 16:37 ET
|
National Brain Tumor Society
Boston, MA, Nov. 13, 2018 (GLOBE NEWSWIRE) -- National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community in the United States, today announced that its funded...
National Brain Tumor Society Brings Realities of Glioblastoma to Congress
18. Mai 2018 16:57 ET
|
National Brain Tumor Society
Washington, D.C., May 18, 2018 (GLOBE NEWSWIRE) -- National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community in the United States, held a congressional...